<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">S.D.C. reports fees for medical education from 
 <funding-source id="gs3">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source> and Pierre Fabre and is a recipient of the IG20774 of Fondazione 
 <funding-source id="gs4">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100005010</institution-id>
   <institution>AIRC</institution>
  </institution-wrap>
 </funding-source>. J.M.P.-G. is a consultant/advisory board member for Roche and Lilly and reports travel and accommodation fees paid by Roche. A.L.-C. plays a leadership role for 
 <funding-source id="gs5">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100003769</institution-id>
   <institution>Eisai</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs6">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100006436</institution-id>
   <institution>Celgene</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs7">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs8">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
   <institution>Pfizer</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs9">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs10">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs11">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source> and MSD; reports stock or other ownership in MedSIR and Initia-Research; is a consultant/advisory board member for 
 <funding-source id="gs12">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs13">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs14">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
   <institution>Pfizer</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs15">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source>, Pierre Fabre, 
 <funding-source id="gs16">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100008067</institution-id>
   <institution>Genomic Health</institution>
  </institution-wrap>
 </funding-source> and GSK; is on the speakers' bureau of and reports honoraria from 
 <funding-source id="gs17">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, AstraZeneca and MSD; reports research funding to the institution from 
 <funding-source id="gs18">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, Foundation Medicine, Pierre Fabre and Agendia and reports travel and accommodation fees paid by 
 <funding-source id="gs19">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs20">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs21">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs22">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
   <institution>Pfizer</institution>
  </institution-wrap>
 </funding-source> and 
 <funding-source id="gs23">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004325</institution-id>
   <institution>AstraZeneca</institution>
  </institution-wrap>
 </funding-source>. G.C. is a consultant/advisory board member for 
 <funding-source id="gs24">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs25">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100010293</institution-id>
   <institution>Seattle Genetics</institution>
  </institution-wrap>
 </funding-source>, Daiichi Sankyo, 
 <funding-source id="gs26">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs27">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100011725</institution-id>
   <institution>Servier</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs28">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004334</institution-id>
   <institution>Merck</institution>
  </institution-wrap>
 </funding-source> Sharp &amp; Dohme, 
 <funding-source id="gs29">GSK</funding-source>, Bioasis and Clovis Oncology; reports honoraria from 
 <funding-source id="gs30">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs31">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs32">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
   <institution>Pfizer</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs33">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004358</institution-id>
   <institution>Samsung</institution>
  </institution-wrap>
 </funding-source>
 <funding-source id="gs34">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs35">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004334</institution-id>
   <institution>Merck</institution>
  </institution-wrap>
 </funding-source> Sharp &amp; Dohme and Daiichi Sankyo and reports research funding to the institution from 
 <funding-source id="gs36">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004334</institution-id>
   <institution>Merck</institution>
  </institution-wrap>
 </funding-source>. J.C. reports stock or other ownership in MedSIR; is a consultant/advisory board member for 
 <funding-source id="gs37">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs38">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100006436</institution-id>
   <institution>Celgene</institution>
  </institution-wrap>
 </funding-source>, Cellestia, 
 <funding-source id="gs39">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004325</institution-id>
   <institution>AstraZeneca</institution>
  </institution-wrap>
 </funding-source>, Biothera Pharmaceuticals, Merus, 
 <funding-source id="gs40">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100010293</institution-id>
   <institution>Seattle Genetics</institution>
  </institution-wrap>
 </funding-source>, Daiichi Sankyo, Erytech, Athenex, Polyphor, 
 <funding-source id="gs41">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs42">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100011725</institution-id>
   <institution>Servier</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs43">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004334</institution-id>
   <institution>Merck</institution>
  </institution-wrap>
 </funding-source> Sharp &amp; Dohme, 
 <funding-source id="gs44">GSK</funding-source>, Leuko, Bioasis and Clovis Oncology; reports honoraria from 
 <funding-source id="gs45">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs46">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004336</institution-id>
   <institution>Novartis</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs47">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100006436</institution-id>
   <institution>Celgene</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs48">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100003769</institution-id>
   <institution>Eisai</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs49">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004319</institution-id>
   <institution>Pfizer</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs50">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004358</institution-id>
   <institution>Samsung</institution>
  </institution-wrap>
 </funding-source> Bioepis, 
 <funding-source id="gs51">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004312</institution-id>
   <institution>Lilly</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs52">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004334</institution-id>
   <institution>Merck</institution>
  </institution-wrap>
 </funding-source> Sharp &amp; Dohme and Daiichi Sankyo and reports research funding to the institution from 
 <funding-source id="gs53">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004337</institution-id>
   <institution>Roche</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs54">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100006413</institution-id>
   <institution>Ariad</institution>
  </institution-wrap>
 </funding-source> Pharmaceuticals, 
 <funding-source id="gs55">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004325</institution-id>
   <institution>AstraZeneca</institution>
  </institution-wrap>
 </funding-source>, 
 <funding-source id="gs56">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100009431</institution-id>
   <institution>Baxalta</institution>
  </institution-wrap>
 </funding-source> GmbH/
 <funding-source id="gs57">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100011725</institution-id>
   <institution>Servier</institution>
  </institution-wrap>
 </funding-source> Affaires, 
 <funding-source id="gs58">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/100004326</institution-id>
   <institution>Bayer</institution>
  </institution-wrap>
 </funding-source> Healthcare, 
 <funding-source id="gs59">
  <institution-wrap>
   <institution-id institution-id-type="doi">10.13039/501100003769</institution-id>
   <institution>Eisai</institution>
  </institution-wrap>
 </funding-source>, F. Hoffmann-La Roche, Guardant Health, Merck Sharp &amp; Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London. A.M. and R.M. declare no competing interests.
</p>
